drug
tapinarof
Marketedupdated 5mo agoby Dermavant Sciences Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying tapinarof
- phase3A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
- phase3Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
- phase1A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
- phase3Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
- phase1Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
- phase2Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma
- phase3Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis
- phase2Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 23, 2027
225 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Dec 18, 2039method-of-use (U-4048)US 12569453
- Nov 13, 2039method-of-use (U-4048)US 11497718
- Nov 13, 2039method-of-use (U-2625)US 11590088
- Nov 13, 2039method-of-use (U-4048)US 11938099
- Nov 13, 2038compositionUS 10647649
- Nov 13, 2038compositionUS 11597692
- May 23, 2036formulationUS 10195160
- May 19, 2036method-of-use (U-2625)US 10426743
- May 19, 2036formulationUS 11458108
- May 19, 2036method-of-use (U-2625)US 11612573
- May 19, 2036formulationUS 11617724
- May 19, 2036formulationUS 11622945
FDA exclusivities (2)
- Dec 12, 2027I-956Indication (3y)1.2y
- May 23, 2027NCENew Chemical Entity (5y)225d
News(2)
- Shionogi makes $2B rare disease play with IntraBio buyWith its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…biospace · 2d ago
- Roivant, the 'inveterate drug hunters', enters commercial era with LisrayaCEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.biospace · 4d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that